Taiwanese biotech manufacturer TaiMed Biologics has secured its first international contract manufacturing deal, marking its entry into the global CDMO (Contract Development and Manufacturing Organization) market. The company will produce clinical trial antibodies for an unnamed U.S. client.
The partnership, pending final contract signing, represents a test case for TaiMed’s ambitions to compete with established global contract manufacturers. While the company touts its FDA-cleared facilities, it faces stiff competition from larger rivals with longer track records in serving international pharmaceutical clients.
TaiMed’s Zhubei facility houses bioreactors ranging from 50 to 2,000 liters and has cleared U.S. FDA inspections in 2022 and 2023. The plant offers services including process development and GMP batch production.
While management expects the deal to boost operations, they haven’t disclosed the contract value or timeline for production start.
The agreement comes as Asian contract manufacturers seek to capitalize on pharmaceutical companies’ efforts to diversify their supply chains beyond traditional manufacturing hubs.
